Synopsis An important component of BP management in hypertensive patients is follow-up. Different periods of time for follow-up are recommended depending on the stage of hypertension, the presence or absence of target organ damage, treatment with antihypertensive medications, and the level of BP control. Recommendations for follow-up are summarized in Figure 4. Recommendation-Specific Supportive Text 1. Nonpharmacological therapy (see Section 6.2) is the preferred therapy for adults with elevated BP and an appropriate first-line therapy for adults with stage 1 hy- pertension who have an estimated 10-year ASCVD risk of <10%. Adherence to and impact of nonpharmacologi- cal therapy should be assessed within 3 to 6 months. 2. Nonpharmacological therapy can help reduce BP in pa- tients with stage 1 hypertension with an estimated 10- yearASCVD risk of 10% and should be used in addition to pharmacological therapy as first-line therapy in such patients (see Section 6.2). 3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and non- pharmacological therapy are important because of the elevated risk of CVD events in this subgroup, especially those with multiple ASCVD risk factors or target organ 4. Prompt management of very high BP is important to re- duce the risk of target organ damage (see Section 11.2). The rapidity of the treatment needed is dependent on the patient s clinical presentation (presence of new or wors- ening target organ damage) and presence or absence of CVD complications, but treatment should be initiated within at least 1 week. 5. Given that the lifetime risk of hypertension exceeds 80% in US adults,S8.1.3-3 it is likely that individuals with a normal BP will develop elevated BP in the future. 